Aurobindo Pharma has announced that it will open a plant capable of manufacturing 50 million dosages of vaccines per year, as the drugmaker launches its vaccine products commercially in 2018.
Aurobindo has formed a joint venture with Hyderabad-based Tergene Biotech, a vaccine development company, for developing pneumococcal conjugate vaccine.
Pneumococcal disease is an infection caused by the Streptococcus pneumoniae bacterium. Infections can result in pneumonia, bacteremia/sepsis, middle-ear infections, and bacterial meningitis.
According to Aurobindo's annual report, “A cGMP pilot plant for clinical lot manufacture is ready and we are now working on clinical trial protocols. The plans are to create infrastructure for 50 million dosage per annum, with the first phase launch being targeted for 25 million doses."
Read the Indian Express release